The company blamed slowing growth in both the psoriasis and
psoriatic arthritis markets in the U.S. due to reimbursement challenges from insurers.
Not exact matches
Three biopharma giants jockey for
market share in
psoriatic arthritis with new data.
The play for
psoriatic arthritis indications makes sense because it would add some depth to the companies»
market penetration in the psoriasis - related disease space, which already has plenty of available options.